{"id":"rbv-48-weeks","safety":{"commonSideEffects":[{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL3659216","moleculeType":"Small molecule","molecularWeight":"435.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the viral RNA polymerase, preventing the replication of the virus. This leads to a decrease in viral load and an improvement in symptoms.","oneSentence":"Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:26.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Hepatitis C in combination with other medications"}]},"trialDetails":[{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C(CHC)","enrollment":74},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT05270759","phase":"","title":"Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-03-01","conditions":"Acute Kidney Injury, Chronic Kidney Disease Stage 5 on Dialysis, Chronic Kidney Failure","enrollment":93},{"nctId":"NCT01120795","phase":"PHASE4","title":"Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2004-02","conditions":"Chronic Hepatitis C","enrollment":55},{"nctId":"NCT00882193","phase":"EARLY_PHASE1","title":"Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-05-01","conditions":"Chronic Hepatitis C, Genotype 1, Relapse","enrollment":2},{"nctId":"NCT06034691","phase":"NA","title":"Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCB","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-09-10","conditions":"Hemodialysis Access Failure","enrollment":40},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT00571714","phase":"NA","title":"Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-04-01","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01866930","phase":"PHASE3","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07-11","conditions":"Chronic Hepatitis C Infection","enrollment":453},{"nctId":"NCT01380938","phase":"PHASE3","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2018-12-01","conditions":"Chronic Hepatitis","enrollment":1150},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":"HIV Infection, Hepatitis C Infection","enrollment":68},{"nctId":"NCT01482767","phase":"PHASE3","title":"Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":"HIV Infections, Hepatitis C","enrollment":262},{"nctId":"NCT01587586","phase":"PHASE2","title":"Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2011-10-18","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT01185028","phase":"PHASE1, PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":"Hepatitis C Infection, HIV Infection","enrollment":8},{"nctId":"NCT00758043","phase":"PHASE3","title":"A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-10","conditions":"Hepatitis C","enrollment":540},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT00943761","phase":"PHASE2","title":"A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-23","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01590225","phase":"PHASE3","title":"Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-28","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01821963","phase":"PHASE3","title":"Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-04","conditions":"Infection","enrollment":1},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01364090","phase":"PHASE4","title":"A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":93},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT01598090","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-14","conditions":"Hepatitis C Virus","enrollment":881},{"nctId":"NCT02247440","phase":"PHASE4","title":"HCV-HIV Co-infected Patient Cohort in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2014-08","conditions":"Hepatitis C Infection, HIV","enrollment":18},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT00665353","phase":"PHASE2","title":"Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV-1 and Hepatitis C Co-Infection","enrollment":19},{"nctId":"NCT00704184","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07-25","conditions":"Hepatitis C","enrollment":95},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT02601976","phase":"PHASE4","title":"Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2010-08","conditions":"Hepatitis C","enrollment":64},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT02758509","phase":"","title":"Impact of Antiviral Therapy on Gastroesophageal Varices.","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2010-01-01","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":237},{"nctId":"NCT00087633","phase":"PHASE4","title":"PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Hepatitis C, Chronic","enrollment":115},{"nctId":"NCT02060058","phase":"PHASE3","title":"Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-11","conditions":"Hepatitis C, Chronic","enrollment":12},{"nctId":"NCT01355289","phase":"PHASE2","title":"Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-11","conditions":"Thrombocytopenia","enrollment":65},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40},{"nctId":"NCT00512278","phase":"PHASE2","title":"Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Nizar Zein","startDate":"2007-07","conditions":"Hepatitis C","enrollment":146},{"nctId":"NCT01265511","phase":"PHASE2","title":"Study of SCY-635, Pegasys and Copegus in Hepatitis C","status":"COMPLETED","sponsor":"Scynexis, Inc.","startDate":"2010-11","conditions":"Hepatitis C Infection","enrollment":10},{"nctId":"NCT02714712","phase":"","title":"SR-BI and Antiviral Treatment Response in HCV","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2015-08","conditions":"Chronic Hepatitis C","enrollment":309},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00800748","phase":"PHASE4","title":"A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02-01","conditions":"Hepatitis C, Chronic","enrollment":372},{"nctId":"NCT01415141","phase":"PHASE4","title":"Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism","status":"WITHDRAWN","sponsor":"University of Vermont","startDate":"2011-07","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01482390","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-30","conditions":"Hepatitis C","enrollment":80},{"nctId":"NCT02006745","phase":"PHASE3","title":"Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2014-01","conditions":"HIV","enrollment":20},{"nctId":"NCT02515279","phase":"","title":"An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00845065","phase":"PHASE3","title":"Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":202},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00687219","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":102},{"nctId":"NCT00705432","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":1472},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00687544","phase":"PHASE4","title":"Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Hepatitis C, Chronic, Hepacivirus, HIV Infections","enrollment":11},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00441584","phase":"PHASE3","title":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic","enrollment":117},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT00081770","phase":"PHASE3","title":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03","conditions":"Hepatitis C, Chronic","enrollment":4469},{"nctId":"NCT00039871","phase":"PHASE3","title":"PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Hepatitis, Hepatitis C, Chronic, Fibrosis","enrollment":2333},{"nctId":"NCT00761735","phase":"PHASE3","title":"5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":94},{"nctId":"NCT01770223","phase":"PHASE4","title":"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT02113631","phase":"NA","title":"Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir","status":"COMPLETED","sponsor":"Louis Stokes VA Medical Center","startDate":"2011-09","conditions":"Hepatitis C, Chronic, Cirrhosis","enrollment":50},{"nctId":"NCT00811967","phase":"PHASE3","title":"Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-02","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":50},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT00483938","phase":"PHASE3","title":"The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Hepatitis C, Chronic","enrollment":236},{"nctId":"NCT02464631","phase":"NA","title":"To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis","status":"TERMINATED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2015-06","conditions":"HCV Related Cirrhosis","enrollment":62},{"nctId":"NCT01937728","phase":"PHASE4","title":"Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-03","conditions":"Hepatitis C","enrollment":542},{"nctId":"NCT01280656","phase":"","title":"A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Hepatitis C, Chronic","enrollment":660},{"nctId":"NCT01903954","phase":"PHASE2","title":"A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Hepatitis C, Chronic","enrollment":283},{"nctId":"NCT01220947","phase":"PHASE2","title":"A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Hepatitis C, Chronic","enrollment":421},{"nctId":"NCT01331850","phase":"PHASE2","title":"A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Hepatitis C, Chronic","enrollment":381},{"nctId":"NCT00869661","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-02","conditions":"Hepatitis C, Chronic","enrollment":413},{"nctId":"NCT00963885","phase":"PHASE2","title":"A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Hepatitis C, Chronic","enrollment":229},{"nctId":"NCT01057667","phase":"PHASE2","title":"A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01296971","phase":"PHASE3","title":"A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Hepatitis C, Chronic","enrollment":""},{"nctId":"NCT00940420","phase":"PHASE4","title":"A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-10","conditions":"Hepatitis C, Chronic","enrollment":2695},{"nctId":"NCT00475072","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-06","conditions":"Hepatitis C, Chronic","enrollment":14},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT01318694","phase":"PHASE3","title":"Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2011-03","conditions":"Hepatitis C","enrollment":1081},{"nctId":"NCT01687257","phase":"PHASE2","title":"Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-07","conditions":"Hepatitis C, Cirrhosis, Portal Hypertension","enrollment":50},{"nctId":"NCT01358864","phase":"PHASE3","title":"Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-06","conditions":"Hepatitis C, Chronic","enrollment":678},{"nctId":"NCT01399619","phase":"PHASE3","title":"Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":310},{"nctId":"NCT01183169","phase":"PHASE2","title":"Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2010-08","conditions":"Hepatitis C","enrollment":459},{"nctId":"NCT02120274","phase":"PHASE4","title":"Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C","status":"TERMINATED","sponsor":"Federal University of São Paulo","startDate":"2014-03","conditions":"RNA Virus Infections, Flaviviridae Infections, Hepatitis C","enrollment":85},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT02761629","phase":"PHASE4","title":"Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"Hepatitis C, Chronic","enrollment":180},{"nctId":"NCT02864199","phase":"PHASE4","title":"A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Hepatitis C, Chronic","enrollment":63},{"nctId":"NCT01066819","phase":"","title":"PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":1656},{"nctId":"NCT01482403","phase":"PHASE2","title":"A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":58},{"nctId":"NCT02641379","phase":"PHASE4","title":"A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":737},{"nctId":"NCT00192647","phase":"PHASE4","title":"A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-08","conditions":"Hepatitis C, Chronic","enrollment":896},{"nctId":"NCT01500772","phase":"PHASE3","title":"Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2012-03","conditions":"Hepatitis C","enrollment":6},{"nctId":"NCT01559844","phase":"PHASE2","title":"Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, Hepatocellular Carcinoma","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RBV(48 weeks)","genericName":"RBV(48 weeks)","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis. Used for Chronic hepatitis C, Hepatitis C in combination with other medications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}